Back to Search
Start Over
Efficacy, safety and feasibility of treatment of chronic HCV infection with directly acting agents in hematopoietic stem cell transplant recipients - Study of infectious diseases working party of EBMT
- Source :
- JOURNAL OF INFECTION, r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau, instname
- Publication Year :
- 2021
-
Abstract
- Objectives: Limited data is available on HCV directly acting agents (DAAs) in haematopoietic stem cell transplant (HSCT) recipients. This study aimed at reporting the characteristics, treatment practices and treatment efficacy in HSCT recipients with chronic HCV. Methods: Prospective observational study from EBMT Infectious Diseases Working Party (IDWP). Patients with chronic HCV infection were included. Results: Between 12/2015 and 07/2018, 45 patients were included: male in 53%; median age 49 years (range, 8-75); acute leukaemia in 48.9%, lymphoma in 17.7%, non-malignant disorders in 22.3%; allogeneic HSCT in 84%; 77.8% no immunosuppressive treatment. Genotypes 1, 2, 3 and 4 were detected in 54.5%, 20.5%, 13.6% and 11.4%, respectively; advanced fibrosis in 40%, including cirrhosis in 11.4%. Overall, 37 (82.2%) patients received DAAs, at a median of 8.4 years after HSCT (16.2% within 6 months from HSCT). Sofosbuvir-based treatment was given to 62.2%. Thirty-five patients completed planned treatment course, with sustained virological response (SVR) of 89.1%, and 94.3% (33/35) in those who completed the treatment. Side effects possibly related to DAAs were reported in 5 (14%) and did not require treatment discontinuation. Conclusions: DAAs treatment was effective, saf e and feasible in this cohort of mainly allogeneic HSCT recipients with mild/moderate liver damage. (c) 2021 The British Infection Association. Published by Elsevier Ltd. All rights reserved.
- Subjects :
- Microbiology (medical)
Male
medicine.medical_specialty
Cirrhosis
Sofosbuvir
Hepacivirus
Transplant
sofosbuvir
Antiviral Agents
Internal medicine
medicine
Humans
business.industry
Hematopoietic Stem Cell Transplantation
Hematopoietic stem cell
DAAs
Middle Aged
medicine.disease
Hepatitis C
Treatment efficacy
Transplant Recipients
Discontinuation
Lymphoma
Treatment
Infectious Diseases
medicine.anatomical_structure
Treatment Outcome
HCV
HSCT
Cohort
Feasibility Studies
Observational study
Drug Therapy, Combination
business
medicine.drug
Subjects
Details
- ISSN :
- 15322742 and 01634453
- Volume :
- 84
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- The Journal of infection
- Accession number :
- edsair.doi.dedup.....a595285d9dd0b421e3f16429d6b3449c